A Phase 3, Randomized, Observer-Blind, Active-Controlled Study to Compare the Immunogenicity of the booster dose of S-268019 to the COMIRNATY intramuscular injection in participants aged 5 to 11 years (COVID-19)
Latest Information Update: 25 Oct 2024
At a glance
- Drugs S 268019 (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Shionogi
Most Recent Events
- 09 Feb 2023 New trial record
- 17 Jan 2023 According to a Shionog media release, the company has initiated a Phase 1/2/3 clinical trial (part2) and Phase 3 additional dose clinical trial in Japanese pediatric subjects of its vaccine S-268019